Clinical Trial Detail

NCT ID NCT03450122
Title Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

myxoid liposarcoma

synovial sarcoma

Therapies

Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305

Aldesleukin + Cyclophosphamide

Aldesleukin + Cyclophosphamide + ID-LV305

Age Groups: adult senior

No variant requirements are available.